1) Riddle M, et al. New insulin glargine formulation: glucose control and
hypoglycaemia in people with type 2 diabetes using basal and mealtime insulin (EDITION
I). Diabetologia. 2013;56 (Suppl 1):A220.
2) Yki-Jarvinen et al. An investigational new insulin U300: glucose control and
hypoglycemia in people with type 2 diabetes on basal insulin and OADs (EDITION II).
Abstract at World Diabetes Congress 2013. Oral presentation OP0075 Abstract.
3) Dahmen R et al New Insulin Glargine U300 Formulation Evens and Prolongs
Steady State PK and PD Profiles During Euglycemic Clamp in Patients With Type 1
Diabetes (T1DM). 73rd Scientific Sessions of the ADA, abstract no. 113-OR.
4) Tillner J, et al. Euglycaemic single dose clamp profile of new insulin
glargine formulation in subjects with type 1 diabetes is flat and prolonged.
Diabetologia. 2013;56 (Suppl 1):A1033.
5) Jax T, et al. New insulin glargine formulation has a flat and prolonged
steady state profile in subjects with type 1 diabetes. Diabetologia. 2013;56 (Suppl
1):A1029.
6) Shiramoto M, et al. Single dose of new insulin glargine Gla-300 formulation
has a flatter and prolonged PK/PD profile than Gla-100 in Japanese subjects with type
1 diabetes. Diabetologia. 2013;56 (Suppl 1):A1031.
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
CONTACT: Contacts: Media Relations : Jack Cox, Tel.: + (33) 1 53 77 46 46,jack.cox@sanofi.com ; Investor Relations : Sébastien Martel, Tel.: + (33)1 53 77 45 45, ir@sanofi.com ; Global Diabetes Communications : PhilMcNamara, Tel.: + 1 908 981 5497, Mobile: + (1) 908 210 4047,philip.mcnamara@sanofi.com ; Global Diabetes Communications : TilmannKiessling, Mobile: +(49) 17 26 15 92 91, tilmann.kiessling@sanofi.com
